Treatment Of Postmenopausal Osteoporosis. Miacalcin injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause.
Calcium-regulating polypeptide
Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
NASAL Postmenopausal osteoporosis: Adult: 200 u daily, alternating nostrils everyday. INTRAVENOUS Emergency treatment of hypercalcaemia: Adult: 5-10 units/kg daily in 500 ml of 0.9% Na CI by slow IV infusion over 6 hr. PARENTERAL Paget’s disease of bone: Adult: Initial dose: 100 u SC/IM daily. Maintenance regimen: 50 u SC/IM 3 times wkly to 100 u daily in patients w/ serious bone deformity or neurologic involvement. Adjunct In hypercalcaemia: Adult: 100 u every 6-8 hr by SC/IM inj. Adjust dose according to response. In severe cases, IV infusion up to 10 units/kg can be given over 6 hr. Max: 400 u every 6-8 hr. Postmenopausal osteoporosis: Adult: 100 u daily or every other day by SC/IM In] together w/ Ca & vit D supplements. Bone pain due to malignant neopiasms: Adult: 200 u 4 times daily or 400 u bid for up to 48 hr by SC/IM inj.
Concurrent use wth cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.
Hypersensitivity. Prior intradermal test preferably done. Children <18 yr, renal impairment. Pregnancy, lactation.
Nausea, vomiting, tingling of hands; Inj site Inflammatory reactions, rashes, facial flushing, bronchospasm, headache, unusual taste, abdominal pain, anorexia. Nasal: Local irritation, ulceration, rhinitis, sinusitis, epistaxis. Anaphylactlc shock.
Animal studies using synthetic salmon calcitonin have shown a decrease in fetal birth weights when rabbits were given doses 14 to 56 times the recommended human dose. There are no controlled data in human pregnancy. Calcitonin is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of calcitonin into human milk.
Symptoms: Flushing, nausea, vomiting and dizziness.
Management: Symptomatic and supportive treatment.
.png&w=384&q=75)